Mediar Therapeutics raises $85 million to develop drugs for diseases that cause scarring in organs; Bellicum Pharmaceuticals halted its Phase I/II trials after a serious adverse event; The Food and Drug Administration says Paxlovid is not associated with COVID rebound.